Spain's Almirall warns of delay in approval for psoriasis drug

IN -

IN—(Reuters) - Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

Thousands to benefit as 'breakthrough' breast cancer drugs approved for NHS use: Annually, 8,000 women in England with previously untreatable advanced breast cancer will have access to drugs shown to slow disease’s progression.. Annually, 8,000 women in England with previously untreatable advanced breast cancer will have access to drugs shown to slow disease’s progression